Patent ID: 11878000
Assignee: DA ZEN THERANOSTICS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 8:
9. The method of claim 1, comprising administering one or more TKI selected from the group consisting of Gefitinib, Icotinib, Erlotinib, Afatinib, Brigatinib, Osimertinib, Dacomitinib, Everolimus, and Lapatinib, in combination with or presence of a sensitizer compound selected from the group consisting of:
a DZ1-SIM ester sensitizer;
a DZ1-SIM amide sensitizer;
a DZ1-CIS ester sensitizer; and
a DZ1-CIS amide sensitizer:
a DZ1-ART ester sensitizer; and
a DZ1-ART amide sensitizer.